Clinical Trials
2 trialsNCT04188548 2025-06-04
EMBER
Eli Lilly and Company
Phase 1 Active not recruiting
NCT01623349 2021-02-10
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
Dana-Farber Cancer Institute
Phase 1 Completed